Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNIK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNIK (WT/Mutant) Recombinant Kinase Domain High purity (>95%), Endotoxin controlled. Sequence Verified via LC-MS. |
View TNIK Products |
| Gene Delivery | TNIK Promise-ORF / Lentivirus Full-length human TNIK ORF for stable cell line generation and signaling assays. |
View TNIK Products |
| Benchmark Ab | Anti-TNIK Recombinant Antibody Sequence-verified positive control for Western Blot, IP, and ELISA validation. |
View TNIK Products |
| Validator | TNIK siRNA Set Target-specific pool for gene knockdown and functional verification. |
View TNIK Products |
| Related Target A | MAP4K4 Highly homologous kinase within the STE20 family; essential for off-target selectivity screening. |
View MAP4K4 Products |
| Related Target B | CTNNB1 (Beta-Catenin) Downstream effector of TNIK in the Wnt pathway; crucial for downstream biomarker validation. |
View CTNNB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| STE20 Kinase Family Off-Target Screening | Homologous kinase panel (MAP4K4, MINK1) available with >95% purity verified by SDS-PAGE. |
| Wnt Pathway Reporter Cell Line Construction | Lentiviral vectors with sequence-verified full-length TNIK for stable host integration. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included for assay standardization. |
| False Positive Kinase Inhibition | Sequence-specific siRNA pool included to validate phenotype specificity. |
Live TNIK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNIK therapeutics is intensifying, with major players shifting focus from traditional oncology indications to fibrotic diseases. As first-generation small molecule inhibitors reach mid-stage clinical trials, the next wave of R&D is targeting tissue-specific delivery and highly selective kinase inhibition to minimize systemic toxicities associated with broader STE20-family inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Insilico Medicine, Novartis | Idiopathic Pulmonary Fibrosis (IPF), Colorectal Cancer | Kinase Selectivity Assays (Need high-purity TNIK & homologous family proteins) |
| siRNA / RNAi | Academic institutions, Biotech startups | Solid Tumors, Fibrosis | In vitro Knockdown Validation (Need sequence-verified siRNA & qPCR control primers) |
| PROTAC | Preclinical discovery programs | Refractory Cancers | Ubiquitination & Degradation Assays (Need stable TNIK-expressing cell lines via Lentivirus) |